Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

[ESC/EAS Guidelines for the management of dyslipidaemias].

Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegría E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs RH, Kjekshus JK, Perrone Filardi P, Riccardi G, Storey RF, David W; Clinical Practice Guidelines Committee of the Spanish Society of Cardiology.

Rev Esp Cardiol. 2011 Dec;64(12):1168.e1-1168.e60. doi: 10.1016/j.recesp.2011.09.014. Review. Spanish. No abstract available.

2.

New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?

Reiner Z.

Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):724-7. doi: 10.1177/1741826711418946. No abstract available.

PMID:
21945917
3.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees.

Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.

4.

Simplifying the approach to the management of dyslipidemia.

Gaziano JM, Gaziano TA.

JAMA. 2009 Nov 18;302(19):2148-9. doi: 10.1001/jama.2009.1685. No abstract available.

PMID:
19920241
5.

Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.

Jialal I, Smith G.

Metab Syndr Relat Disord. 2012 Jun;10(3):159-60. doi: 10.1089/met.2012.1500. Epub 2012 May 8. No abstract available.

PMID:
22568574
6.

[The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].

Olsson AG.

Lakartidningen. 2011 Nov 23-29;108(47):2442-3. Swedish. No abstract available.

PMID:
22468387
7.

(8) Cardiovascular disease and risk management.

American Diabetes Association.

Diabetes Care. 2015 Jan;38 Suppl:S49-57. doi: 10.2337/dc15-S011. No abstract available.

PMID:
25537708
8.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees.

Atherosclerosis. 2011 Jul;217 Suppl 1:S1-44. doi: 10.1016/j.atherosclerosis.2011.06.012. Review. No abstract available. Erratum in: Atherosclerosis. 2011 Jul;217(1):2.

PMID:
21723445
9.

Drug therapy of diabetic dyslipidemia: do the statins suffice?

Mooradian AD.

Am J Ther. 2015 Jan-Feb;22(1):87-8. doi: 10.1097/MJT.0b013e318293b0f9. No abstract available.

PMID:
23728161
10.

Lipids, statins and cardiovascular disease.

Cheifitz R.

Climacteric. 2008 Aug;11(4):347-8; author reply 348-50. doi: 10.1080/13697130802242632. No abstract available.

PMID:
18645702
11.

From the editor: drugs, genes, and lipoproteins.

Brown WV.

J Clin Lipidol. 2014 Nov-Dec;8(6):529-30. doi: 10.1016/j.jacl.2014.09.012. Epub 2014 Oct 8. No abstract available.

PMID:
25499933
12.

[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].

Pérez A.

Endocrinol Nutr. 2010 Dec;57(10):457-9. doi: 10.1016/j.endonu.2010.05.010. Epub 2010 Aug 4. Spanish. No abstract available.

PMID:
20688585
13.

Commentary: Controversies in NICE guidance on lipid modification for the prevention of cardiovascular disease.

Cappuccio FP.

BMJ. 2008 May 31;336(7655):1248-9. doi: 10.1136/bmj.39580.424352.AD. No abstract available.

14.

Total lipid management and residual risk: beyond statin therapy.

Evans M.

Br J Hosp Med (Lond). 2011 Mar;72(3):132-6. Review.

PMID:
21475092
15.

Pharmacologic interactions of multidrug therapy for dyslipidemia.

Mehta N, deGoma EM.

Curr Atheroscler Rep. 2013 Feb;15(2):303. doi: 10.1007/s11883-012-0303-7. Review.

PMID:
23299643
16.

Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough?

Kostapanos MS, Katsiki N, Elisaf MS, Mikhailidis DP.

Curr Vasc Pharmacol. 2012 Mar;10(2):173-7. No abstract available.

PMID:
22250844
17.
18.

Lipids: new guidelines, intensive treatment, and future directions.

Jones PH.

Tex Heart Inst J. 2006;33(2):180-3. No abstract available.

19.

Role of dyslipidemia in patients with chronic kidney disease.

Marino A, Tannock LR.

Postgrad Med. 2013 Jul;125(4):28-37. doi: 10.3810/pgm.2013.07.2676. Epub 2013 Jul 10. Review. No abstract available.

PMID:
23842535
20.

Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance.

Cooper A, O'Flynn N; Guideline Development Group.

BMJ. 2008 May 31;336(7655):1246-8. doi: 10.1136/bmj.39554.624086.AD. Review. No abstract available. Erratum in: BMJ. 2014;349:4718.

Supplemental Content

Support Center